Shoko Ito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shoko Ito has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Iekuni Oh
Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan
3 shared publicationsKaoru Hatano
Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan
3 shared publications- Kazuya Sato
Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan
3 shared publications Masahiro Ashizawa
Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan
3 shared publicationsRyoko Yamasaki
Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan
3 shared publications- Yoshinobu Kanda
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
3 shared publications
Latest Publications
- 2 May 2026
- Published by Elsevier in Environmental Pollution
- Vol. 402, 128210
Corrigendum to “Response of 137Cs dynamics in dam lakes to temperature and weather conditions” [Environ. Pollut. 378, 126445]
- 2 May 2026
- Published by Elsevier in Environmental Pollution
- Vol. 402, 128210
Corrigendum to “Response of 137Cs dynamics in dam lakes to temperature and weather conditions” [Environ. Pollut. 378, 126445]
- 9 November 2020
- Published by Springer Nature in Annals of Hematology
- Vol. 100 (2) , 345-352
Clinical association between thyroid disease and immune thrombocytopenia
Immune thrombocytopenia (ITP) can coexist with autoimmune thyroid disease. However, the detailed clinical features remain unknown. We retrospectively reviewed 248 patients with newly diagnosed ITP in our institute for whom we had thyroid function data at diagnosis between 2000 and 2019. Of the 248 patients with ITP, 74 patients also had thyroid disease, including 36 with overt thyroid disease (13 Graves’ disease and 23 Hashimoto’s thyroiditis) and 38 with subclinical thyroid disease (3 hyperthyroidism and 35 hypothyroidism). ITP and thyroid disease were concurrently diagnosed in 54 patients. Female sex and positivity for antinuclear antibodies (ANA) were significantly associated with thyroid diseases. Platelet-associated immunoglobulin G (PAIgG) levels in patients with Graves’ disease were higher than those in patients with Hashimoto’s thyroiditis. Platelet counts were similar among euthyroid patients and patients with thyroid disease. Thrombopoietin-receptor agonist was administered more frequently in patients with thyroid disease. The cumulative incidences of thrombosis and bleeding and overall survival did not differ between patients with and without thyroid disease. Treatment for thyroid disease in 22 patients improved thrombocytopenia in 21 patients, especially in 4 patients who were not treated for ITP. This study demonstrated that thyroid diseases were commonly found in patients with ITP. Treatment of the underlying thyroid disease may improve thrombocytopenia.
- 9 November 2020
- Published by Springer Nature in Annals of Hematology
- Vol. 100 (2) , 345-352
Clinical association between thyroid disease and immune thrombocytopenia
Immune thrombocytopenia (ITP) can coexist with autoimmune thyroid disease. However, the detailed clinical features remain unknown. We retrospectively reviewed 248 patients with newly diagnosed ITP in our institute for whom we had thyroid function data at diagnosis between 2000 and 2019. Of the 248 patients with ITP, 74 patients also had thyroid disease, including 36 with overt thyroid disease (13 Graves’ disease and 23 Hashimoto’s thyroiditis) and 38 with subclinical thyroid disease (3 hyperthyroidism and 35 hypothyroidism). ITP and thyroid disease were concurrently diagnosed in 54 patients. Female sex and positivity for antinuclear antibodies (ANA) were significantly associated with thyroid diseases. Platelet-associated immunoglobulin G (PAIgG) levels in patients with Graves’ disease were higher than those in patients with Hashimoto’s thyroiditis. Platelet counts were similar among euthyroid patients and patients with thyroid disease. Thrombopoietin-receptor agonist was administered more frequently in patients with thyroid disease. The cumulative incidences of thrombosis and bleeding and overall survival did not differ between patients with and without thyroid disease. Treatment for thyroid disease in 22 patients improved thrombocytopenia in 21 patients, especially in 4 patients who were not treated for ITP. This study demonstrated that thyroid diseases were commonly found in patients with ITP. Treatment of the underlying thyroid disease may improve thrombocytopenia.
- 18 December 2019
- Published by Springer Nature in Annals of Hematology
- Vol. 99 (1) , 49-55
Evaluation of thrombotic events in patients with immune thrombocytopenia
Immune thrombocytopenia (ITP) has been reported to be associated with thrombotic events. The incidence of thrombosis in 303 newly diagnosed ITP patients in our institute between 2000 and 2016 was retrospectively reviewed. During a median follow-up of 3.6 years, 16 thrombotic events (12 arterial and four venous) occurred. The median platelet count at thrombotic events was 102 × 109/l. At 10 years, the cumulative thrombosis incidence was 10%. A univariate analysis showed that smoking, hypertension, male gender, a history of thrombosis, and atrial fibrillation (Af) were significantly associated with the occurrence of thrombosis, and a multivariate analysis identified smoking and Af as independent risk factors. The thrombotic risk was not increased by lupus anticoagulant positivity or ITP treatment. At 5 years, the cumulative incidence of bleeding and overall survival probability was 5.6% and 92%, respectively. This study demonstrates that smoking and Af were associated with an increased risk of thrombosis. Previously identified risk factors were not confirmed in these Japanese ITP patients.
- 18 December 2019
- Published by Springer Nature in Annals of Hematology
- Vol. 99 (1) , 49-55
Evaluation of thrombotic events in patients with immune thrombocytopenia
Immune thrombocytopenia (ITP) has been reported to be associated with thrombotic events. The incidence of thrombosis in 303 newly diagnosed ITP patients in our institute between 2000 and 2016 was retrospectively reviewed. During a median follow-up of 3.6 years, 16 thrombotic events (12 arterial and four venous) occurred. The median platelet count at thrombotic events was 102 × 109/l. At 10 years, the cumulative thrombosis incidence was 10%. A univariate analysis showed that smoking, hypertension, male gender, a history of thrombosis, and atrial fibrillation (Af) were significantly associated with the occurrence of thrombosis, and a multivariate analysis identified smoking and Af as independent risk factors. The thrombotic risk was not increased by lupus anticoagulant positivity or ITP treatment. At 5 years, the cumulative incidence of bleeding and overall survival probability was 5.6% and 92%, respectively. This study demonstrates that smoking and Af were associated with an increased risk of thrombosis. Previously identified risk factors were not confirmed in these Japanese ITP patients.
- Open Access
- 25 January 2019
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 13 (Supplement) , S301
P387 Efficacy of combination therapy of fresh faecal microbiota transplantation and triple-antibiotic therapy for ulcerative colitis
We previously demonstrated that fresh faecal-microbiota transplantation (FMT) following triple-antibiotic therapy [amoxicillin, fosfomycin, and metronidazole (AFM); A-FMT] induced dramatic changes in the phylum Bacteroidetes, which constitutes a critical factor correlated with clinical responses.1 Furthermore, we also reported that A-FMT combination therapy contributed to the microbiological improvement of intestinal dysbiosis in UC patients via successful transplantation of live Bacteroidetes cells from donors.2 Eradication of dysbiotic indigenous Bacteroidetes species by AFM pre-treatment may promote the entry of living Bacteroidetes cells, thereby improving the dysbiosis of intestinal microbiota induced by UC. Here, we evaluated the efficacy of A-FMT compared with AFM monotherapy and examined factors correlated with clinical response. This was an open-label, non-randomised, prospective control study. These patients were diagnosed with active UC, with a Lichtiger’s Clinical Activity Index (CAI) of 5 or more, or with an endoscopic Mayo clinic score of 1 or more, between July 2014 and March 2017. Patients’ spouses or relatives were selected as donor candidates. AFM was administered to patients with UC for 2 weeks, and up to 2 days before fresh FMT. Donor faecal samples were collected on the day of administration and transferred into the patient’s colon via colonoscopy within 6 h. The clinical features of UC were judged using CAI before treatment and 4 weeks after treatment. Clinical responses were defined as a CAI of less than 10 points and a decrease of 3 or more points, and clinical remission was defined as a CAI of 3 points or less. Patients with mild-to-severe active UC (n = 55 A-FMT; n = 37 AFM) were included in this assessment. Seventy-nine patients completed this assessment (n = 46 A-FMT; n = 32 AFM). At 4 weeks after treatment, clinical responses and were observed in 31 patients {Per Protocol Set (PPS): 67.3%) in A-FMT, which higher than in AFM (PPS:56.2%)}. In A-FMT, the clinical remission was observed to be higher than AFM (A-FMT41.3%, AFM18.7%; p = 0.06). In A-FMT, endoscopic sum score was associated with clinical responses (responders 7.5 ± 3.2, non-responders 5.1 ± 3.6; p = 0.03), and clinical responses and remission were significantly higher in proctitis than other type of colitis (n = 38, 8; p = 0.03, p = 0.005). In addition, decrease of CAI was significantly higher in users of anti-TNFα and PSL than in non-users (p = 0.01, p = 0.01). These factors correlated with clinical responses were not observed in AFM monotherapy. Further follow-up studies are required to evaluate the long-term efficacy of this FMT protocol, and it is possible that this protocol may become a useful strategy for the management of patients with UC. References 1. Ishikawa D, Sasaki T, Osada T, et al. Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis. Inflamm Bowel Dis 2017;23:116–125. 2. Ishikawa D, Sasaki T, Takahashi M, et al. The microbial composition of bacteroidetes species in ulcerative colitis is effectively improved by combination therapy with fecal microbiota transplantation and antibiotics. Inflamm Bowel Dis 2018;24:2590–2598.
- 25 January 2019
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 13 (Supplement) , S301
Open AccessP387 Efficacy of combination therapy of fresh faecal microbiota transplantation and triple-antibiotic therapy for ulcerative colitis
We previously demonstrated that fresh faecal-microbiota transplantation (FMT) following triple-antibiotic therapy [amoxicillin, fosfomycin, and metronidazole (AFM); A-FMT] induced dramatic changes in the phylum Bacteroidetes, which constitutes a critical factor correlated with clinical responses.1 Furthermore, we also reported that A-FMT combination therapy contributed to the microbiological improvement of intestinal dysbiosis in UC patients via successful transplantation of live Bacteroidetes cells from donors.2 Eradication of dysbiotic indigenous Bacteroidetes species by AFM pre-treatment may promote the entry of living Bacteroidetes cells, thereby improving the dysbiosis of intestinal microbiota induced by UC. Here, we evaluated the efficacy of A-FMT compared with AFM monotherapy and examined factors correlated with clinical response. This was an open-label, non-randomised, prospective control study. These patients were diagnosed with active UC, with a Lichtiger’s Clinical Activity Index (CAI) of 5 or more, or with an endoscopic Mayo clinic score of 1 or more, between July 2014 and March 2017. Patients’ spouses or relatives were selected as donor candidates. AFM was administered to patients with UC for 2 weeks, and up to 2 days before fresh FMT. Donor faecal samples were collected on the day of administration and transferred into the patient’s colon via colonoscopy within 6 h. The clinical features of UC were judged using CAI before treatment and 4 weeks after treatment. Clinical responses were defined as a CAI of less than 10 points and a decrease of 3 or more points, and clinical remission was defined as a CAI of 3 points or less. Patients with mild-to-severe active UC (n = 55 A-FMT; n = 37 AFM) were included in this assessment. Seventy-nine patients completed this assessment (n = 46 A-FMT; n = 32 AFM). At 4 weeks after treatment, clinical responses and were observed in 31 patients {Per Protocol Set (PPS): 67.3%) in A-FMT, which higher than in AFM (PPS:56.2%)}. In A-FMT, the clinical remission was observed to be higher than AFM (A-FMT41.3%, AFM18.7%; p = 0.06). In A-FMT, endoscopic sum score was associated with clinical responses (responders 7.5 ± 3.2, non-responders 5.1 ± 3.6; p = 0.03), and clinical responses and remission were significantly higher in proctitis than other type of colitis (n = 38, 8; p = 0.03, p = 0.005). In addition, decrease of CAI was significantly higher in users of anti-TNFα and PSL than in non-users (p = 0.01, p = 0.01). These factors correlated with clinical responses were not observed in AFM monotherapy. Further follow-up studies are required to evaluate the long-term efficacy of this FMT protocol, and it is possible that this protocol may become a useful strategy for the management of patients with UC. References 1. Ishikawa D, Sasaki T, Osada T, et al. Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis. Inflamm Bowel Dis 2017;23:116–125. 2. Ishikawa D, Sasaki T, Takahashi M, et al. The microbial composition of bacteroidetes species in ulcerative colitis is effectively improved by combination therapy with fecal microbiota transplantation and antibiotics. Inflamm Bowel Dis 2018;24:2590–2598.
- 1 October 2018
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 24 (10) , 812-814
False-positive elevation of 1,3-beta-D-glucan caused by continuous administration of penicillin G
- 1 October 2018
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 24 (10) , 812-814
False-positive elevation of 1,3-beta-D-glucan caused by continuous administration of penicillin G